Randomised controlled trial of mesalazine in IBS

Giovanni Barbara, Cesare Cremon, Vito Annese, Guido Basilisco, Franco Bazzoli, Massimo Bellini, Antonio Benedetti, Luigi Benini, Fabrizio Bossa, Paola Buldrini, Michele Cicala, Rosario Cuomo, Bastianello Germanà, Paola Molteni, Matteo Neri, Marcello Rodi, Alfredo Saggioro, Maria Lia Scribano, Maurizio Vecchi, Giorgio ZoliRoberto Corinaldesi, Vincenzo Stanghellini

Research output: Contribution to journalArticlepeer-review


Objective: Low-grade intestinal inflammation plays a role in the pathophysiology of IBS. In this trial, we aimed at evaluating the efficacy and safety of mesalazine in patients with IBS. Design: We conducted a phase 3, multicentre, tertiary setting, randomised, double-blind, placebo-controlled trial in patients with Rome III confirmed IBS. Patients were randomly assigned to either mesalazine, 800 mg, or placebo, three times daily for 12 weeks, and were followed for additional 12 weeks. The primary efficacy endpoint was satisfactory relief of abdominal pain/discomfort for at least half of the weeks of the treatment period. The key secondary endpoint was satisfactory relief of overall IBS symptoms. Supportive analyses were also performed classifying as responders patients with a percentage of affirmative answers of at least 75% or >75% of time. Results: A total of 185 patients with IBS were enrolled from 21 centres. For the primary endpoint, the responder patients were 68.6% in the mesalazine group versus 67.4% in the placebo group (p=0.870; 95% CI -12.8 to 15.1). In explorative analyses, with the 75% rule or >75% rule, the percentage of responders was greater in the mesalazine group with a difference over placebo of 11.6% (p=0.115; 95% CI -2.7% to 26.0%) and 5.9% (p=0.404; 95% CI -7.8% to 19.4%), respectively, although these differences were not significant. For the key secondary endpoint, overall symptoms improved in the mesalazine group and reached a significant difference of 15.1% versus placebo (p=0.032; 95% CI 1.5% to 28.7%) with the >75% rule. Conclusions: Mesalazine treatment was not superior than placebo on the study primary endpoint. However, a subgroup of patients with IBS showed a sustained therapy response and benefits from a mesalazine therapy. Trial registration number: ClincialTrials.gov number, NCT00626288.

Original languageEnglish
Pages (from-to)82-90
Number of pages9
Issue number1
Publication statusPublished - Jan 1 2016

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Randomised controlled trial of mesalazine in IBS'. Together they form a unique fingerprint.

Cite this